Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection | Zendy

David P. Serota | Zendy; Harold A. Franch | Zendy; Emily J. Cartwright | Zendy

Open Access

Acute Kidney Injury in a Patient on Tenofovir Alafenamide Fumarate After Initiation of Treatment for Hepatitis C Virus Infection

Author(s) -

David P. Serota,

Harold A. Franch,

Emily J. Cartwright

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy189

Subject(s) - tenofovir alafenamide , medicine , ledipasvir , sofosbuvir , regimen , coinfection , human immunodeficiency virus (hiv) , cobicistat , virology , gastroenterology , hepatitis c virus , virus , viral load , antiretroviral therapy , ribavirin

HIV treatment with tenofovir alafenamide fumarate (TAF) has decreased renal toxicity compared with tenofovir disoproxil fumarate in clinical trials. We report the case of a patient with HIV/HCV coinfection who was started on a TAF-based HIV regimen and developed acute kidney injury that worsened with the addition of sofosbuvir-ledipasvir.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research